tradingkey.logo
tradingkey.logo
Search

Moderna Inc

MRNA
Add to Watchlist
158.070USD
+12.450+8.55%
Close 09-16 16:00ET
63.07BMarket Cap
LossP/E TTM
After-hours 16:11 (ET)157.900USD-0.030-0.02%

More Details of Moderna Inc Company

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).

Moderna Inc Profile

Ticker SymbolMRNA
Company nameModerna Inc
IPO dateDec 07, 2018
CEOBancel (Stephane)
Number of employees5800
Security typeOrdinary Share
Fiscal year-endDec 07
Address325 Binney Street
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142
Phone16177146500
Websitehttps://www.modernatx.com/
Ticker SymbolMRNA
IPO dateDec 07, 2018
CEOBancel (Stephane)

Company Executives of Moderna Inc

Name
Name/Position
Position
Shareholding
Change
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.65M
+0.29%
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.65M
+0.29%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
--
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
81.34K
+8.87%
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
81.34K
+8.87%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
74.38K
+9.91%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
74.38K
+9.91%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
19.32K
+84.03%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
19.32K
+84.03%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
4.76K
+85.23%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.65M
+0.29%
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.65M
+0.29%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
--
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
81.34K
+8.87%
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
81.34K
+8.87%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
74.38K
+9.91%

FAQs

Who are the top five shareholders of Moderna Inc?

The top five shareholders of Moderna Inc are: Dr. Stephen Hoge, M.D.

How many institutions hold shares of Moderna Inc (MRNA)?

As of 2026Q1, 1886 institutions hold shares of Moderna Inc, with a combined market value of approximately 313.06M, accounting for 78.90% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 10100814.00.

What is the biggest source of revenue for Moderna Inc?

In 2026Q1, the COVID business generated the highest revenue for Moderna Inc, amounting to 91.00M and accounting for 96.81% of total revenue.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.